Skip to Content

Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

Securities Class Action

  • Date:
  • 10/4/2019
  • Company Name:
  • Aclaris Therapeutics, Inc.
  • Stock Symbol:
  • ACRS
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

NEW YORK, October 4, 2019 – Bragar Eagel & Squire is investigating certain officers and directors of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) following a class action complaint that was filed against Aclaris on July 30, 2019.

The complaint alleges that throughout the class period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the company’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales; (2) that, as a result, the company was reasonably likely to face regulatory scrutiny; and (3) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are a long-term stockholder of Aclaris securites, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Aclaris Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: